Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02543346 · ClinicalTrials.gov registry record · Phase 4
Comparability and Standardization of Controlled Allergen Challenge Facilities
A Phase 4 study of Allergic Rhinitis, sponsored by Queen's University.
- Completed
- Registry status
- Phase 4
- Development phase
- 98
- Enrollment target
- 2
- Study locations
NCT02543346 is a Phase 4 study of Allergic Rhinitis that has completed, run by Queen's University. The registered enrollment target is 98 participants, roughly in line with the 101-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target. The trial reports 2 study locations across 2 states.
The verdict
NCT02543346, a Phase 4 study of Allergic Rhinitis, has completed, sponsored by Queen's University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 98 participants
- Enrollment target
- 2
- Study locations
Study Summary
Allergen challenge facilities have been utilized for many years in clinical drug trials studying onset of action, proof of concept, duration of action, and efficacy. Each facility has somewhat different design characteristics and pollen dispersal technologies. Facilities are located in disparate geographic areas and have populations of participants who are sensitized to allergens unique to that area. Therefore, facilities have operated as single sites with little effort to evaluate facility comparability or to attempt standardization across facilities. The purpose of this study is to compare the two sites and assess whether the sites are able to achieve similar symptom scores.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Cetirizine
Study Locations (2)
Texas
- Biogenics Research Chamber - San Antonio
Ontario
- Kingston General Hospital - Kingston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02543346
The ClinicalTrials.gov registry entry for NCT02543346 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 101-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target. The listed sponsor is Queen's University, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Rhinitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02543346 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Ontario.
Frequently Asked Questions
What is clinical trial NCT02543346 about?
NCT02543346 is a clinical study titled "Comparability and Standardization of Controlled Allergen Challenge Facilities". Allergen challenge facilities have been utilized for many years in clinical drug trials studying onset of action, proof of concept, duration of action, and efficacy. Each facility has somewhat different design characteristics and pollen dispersal technologies. Facilities are located in disparate geo...
What is the current status of trial NCT02543346?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 98 participants. The study started on 2015-10. Estimated completion is 2016-05.
What conditions does trial NCT02543346 study?
This clinical trial studies the following conditions: Allergic Rhinitis.
What interventions are being tested in trial NCT02543346?
The interventions under investigation include: Placebo (OTHER), Cetirizine (DRUG).
Who is sponsoring clinical trial NCT02543346?
This trial is sponsored by Queen's University, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02543346 being conducted?
This trial has 2 study locations across Texas, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease
ACTIVE NOT RECRUITING · Phase 4
-
Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine
COMPLETED · Phase 4
-
The Effect of Cetirizine on Bronchoconstriction
COMPLETED · Phase 4
-
Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine
COMPLETED · Phase 4
-
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)
COMPLETED · Phase 4
-
Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.